Jul 1, 2026 07:05AM
Jun 22, 2026 07:06AM
Jun 16, 2026 07:31AM
May 14, 2026 07:31AM
May 8, 2026 05:45AM
Mar 31, 2026 04:31PM
Mar 26, 2026 07:31AM Cognition Therapeutics reports 2025 loss of $23.5 million
Mar 17, 2026 07:31AM
Mar 2, 2026 07:31AM
Feb 5, 2026 07:31AM
Jan 27, 2026 07:31AM
Dec 18, 2025 04:22PM
Dec 18, 2025 04:09PM
Dec 3, 2025 07:30AM Cognition Therapeutics completes enrollment in expanded access program
Nov 6, 2025 08:13AM
Sep 3, 2025 07:30AM
Aug 12, 2025 04:05PM
Jul 21, 2025 07:31AM
Jul 14, 2025 07:07AM
Jul 10, 2025 07:31AM
Jul 3, 2025 06:49AM H.C. Wainwright Reiterates Buy Rating on Cognition Therapeutics (CGTX)
Jul 1, 2025 07:31AM
Jun 26, 2025 06:45AM
Jun 9, 2025 06:48AM
May 27, 2025 06:38AM
May 8, 2025 07:31AM
May 7, 2025 07:31AM
Apr 1, 2025 07:31AM Cognition Therapeutics (CGTX) Presents Results Showing Impact of Zervimesine on Alzheimer’s Disease Processes
Mar 25, 2025 07:31AM
Mar 24, 2025 06:42AM
Mar 21, 2025 06:43AM
Mar 12, 2025 04:06PM
Feb 27, 2025 07:34AM
Feb 26, 2025 07:00AM
Feb 20, 2025 07:31AM Cognition Therapeutics (CGTX) Announces Publication of Commercial Manufacturing Process for Lead Alzheimer’s Candidate, Zervimesine
Dec 19, 2024 06:40AM
Dec 18, 2024 07:23AM
Nov 26, 2024 07:32AM
Nov 13, 2024 07:31AM
Nov 4, 2024 06:49AM
Oct 29, 2024 12:57PM
Aug 22, 2024 07:32AM Cognition Therapeutics (CGTX) Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
Aug 8, 2024 08:18AM
Aug 6, 2024 07:32AM
Jul 31, 2024 06:42AM
Jul 29, 2024 07:01AM
Jul 29, 2024 06:56AM
Jul 2, 2024 07:32AM

425,763 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All